Breast cancer:
Indications for: ESTRACE
Palliative treatment of metastatic breast cancer in select patients (see full labeling).
Adult Dosage:
10mg 3 times daily for at least 3 months.
Children Dosage:
Not applicable.
ESTRACE Contraindications:
Thrombophlebitis. Thromboembolic disorders. Cerebrovascular disorders. Abnormal undiagnosed genital bleeding. Estrogen-depended neoplasias. Liver dysfunction or disease. Pregnancy (Cat. X).
Boxed Warning:
Endometrial cancer. Breast cancer. Cardiovascular disorders. Probable dementia.
ESTRACE Warnings/Precautions:
Asthma (2mg tabs). Hepatic dysfunction. Conditions aggravated by fluid retention. Cardiovascular disorders, arterial vascular disease, and risks factors (eg, hypertension, diabetes, obesity, SLE). Familial hyperlipoprotenemia. Monitor BP. Discontinue if jaundice occurs and before prolonged immobilization (eg, surgery). Nursing mothers.
ESTRACE Classification:
Estrogen.
Adverse Reactions:
See full labeling. GI upset, headache, hypertension, edema, hypercalcemia, gallbladder or thromboembolic disease, gynecomastia, impotence, impaired glucose tolerance.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
Menopause and HRT:
Indications for: ESTRACE
Moderate-to-severe vasomotor symptoms of menopause. Atrophic vaginitis. Hypoestrogenism. Osteoporosis prevention.
Adult Dosage:
Menopause, hypoestrogenism: 1–2mg daily, given cyclically (3 weeks on, 1 week off). Osteoporosis prevention (begin therapy soon after menopause): 0.5mg daily for 3 weeks, then stop for 1 week, then recycle; adjust. Reevaluate periodically.
Children Dosage:
Not applicable.
ESTRACE Contraindications:
Breast or estrogen-dependent cancer. Thrombophlebitis. Thromboembolic disorders. Undiagnosed abnormal genital bleeding. Pregnancy (Cat.X).
Boxed Warning:
Endometrial cancer. Breast cancer. Cardiovascular disorders. Probable dementia.
ESTRACE Warnings/Precautions:
Increased risk of endometrial carcinoma or hyperplasia in women with intact uterus (adding progestin is essential). Increased risk of cardiovascular events (eg, MI, stroke, VTE); discontinue if occurs. Manage risk factors for cardiovascular disease and venous thromboembolism appropriately. Breast cancer. Risk of probable dementia in women >65yrs of age. Asthma (2mg tabs). Hepatic dysfunction. Conditions aggravated by fluid retention. Familial hyperlipoproteinemia. Do initial complete physical examination and repeat annually (include BP, mammogram, and PAP smear). Discontinue if jaundice occurs. Nursing mothers.
ESTRACE Classification:
Estrogen.
Adverse Reactions:
See full labeling. Mastodynia, breast secretion, uterine bleeding, dysmenorrhea, amenorrhea, GI upset, headache, hypertension, edema, hypercalcemia, gallbladder or thromboembolic disease, skin changes.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
Prostate and other male cancers:
Indications for: ESTRACE
Palliative treatment of androgen-dependent advanced prostate cancer.
Adult Dosage:
1–2mg 3 times daily.
Children Dosage:
Not applicable.
ESTRACE Contraindications:
Thrombophlebitis. Thromboembolic disorders. Cerebrovascular disorders. Abnormal undiagnosed genital bleeding. Estrogen-depended neoplasias. Liver dysfunction or disease. Pregnancy (Cat. X).
Boxed Warning:
Endometrial cancer. Breast cancer. Cardiovascular disorders. Probable dementia.
ESTRACE Warnings/Precautions:
Asthma (2mg tabs). Hepatic dysfunction. Conditions aggravated by fluid retention. Cardiovascular disorders, arterial vascular disease, and risks factors (eg, hypertension, diabetes, obesity, SLE). Familial hyperlipoprotenemia. Monitor BP. Discontinue if jaundice occurs and before prolonged immobilization (eg, surgery). Nursing mothers.
ESTRACE Classification:
Estrogen.
Adverse Reactions:
See full labeling. GI upset, headache, hypertension, edema, hypercalcemia, gallbladder or thromboembolic disease, gynecomastia, impotence, impaired glucose tolerance.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
